Gyre Therapeutics has completed its acquisition of Cullgen in an all-stock deal valued at about $300 million, forming a fully integrated biopharmaceutical company based in the US and China. The combined company now offers a commercial product, ETUARY®, for lung fibrosis in China, and a robust pipeline including treatments for liver fibrosis and inflammatory diseases. Leadership changes include Dr. Ying Luo becoming CEO and President, with Ping Zhang remaining Chairman. The acquisition strengthens Gyre's position with innovative targeted protein degrader therapies and supports future global growth, with ongoing clinical trials and regulatory progress in China and plans for expansion outside China, including the US.
Pepeto has completed a significant security upgrade on its DeFi exchange platform, drawing strong interest from XRP whale investors during its rapidly filling 2026 presale. This surge is linked to bullish XRP price forecasts and upcoming pro-crypto p...
Optimism's OP Stack revenue-sharing model, which generates around $4.5 million annually for ecosystem funding, is under threat as Base, its largest contributor, signals potential withdrawal from revenue sharing. This model requires chains to pay eith...
IKIGAI Trading Academy, led by Qamar Zaman, has released Flight Path, a market-structure projection tool for SPX and SPY day traders. The tool helps traders plan trades by mapping bullish and bearish paths based on market structure before the open, e...
OpenAI's GPT-5.6 Sol model scored 88.8% on the TerminalBench 2.1 coding benchmark, significantly surpassing Anthropic's Claude Opus 4.8, which scored 78.9%. The Sol Ultra variant achieved an even higher score of 91.9% by using advanced techniques to ...
Bitcoin challenged the $63K level but failed to surpass it, bouncing from $58.5K earlier in July. Over $143 million in short liquidations indicate many traders were caught off-guard, suggesting a possible bullish reversal rather than just a short squ...
